- Home
- SBH vs GLUE Comparison
SBH vs GLUE Comparison
Compare SBH & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SBH | GLUE |
|---|---|---|
| Founded | 1964 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | 2006 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SBH | GLUE |
|---|---|---|
| Price | $15.81 | $12.60 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | $17.25 | ★ $32.00 |
| AVG Volume (30 Days) | 955.0K | ★ 1.0M |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.17 | N/A |
| EPS | ★ 1.43 | N/A |
| Revenue | ★ $3,701,424,000.00 | $123,672,000.00 |
| Revenue This Year | $2.20 | N/A |
| Revenue Next Year | $1.82 | $2.45 |
| P/E Ratio | ★ $11.25 | $72.42 |
| Revenue Growth | N/A | ★ 63.54 |
| 52 Week Low | $11.54 | $6.17 |
| 52 Week High | $17.92 | $25.77 |
Technical Indicators
Market Signals| Indicator | SBH | GLUE |
|---|---|---|
| Relative Strength Index (RSI) | 49.98 | 30.19 |
| Support Level | $14.92 | N/A |
| Resistance Level | $17.02 | $15.00 |
| Average True Range (ATR) | 0.52 | 0.74 |
| MACD | -0.11 | 0.09 |
| Stochastic Oscillator | 39.66 | 1.75 |
Price Performance
Historical ComparisonAbout SBH Sally Beauty Holdings Inc. (Name to be changed from Sally Holdings Inc.)
Sally Beauty Holdings Inc is a professional beauty-products retailer based in the United States. The company operates throughout the United States, Puerto Rico, the United Kingdom, Belgium, Canada, Chile, Mexico, Peru, France, Ireland, Spain, Germany, Netherlands, and other geographical regions. The company operates through two business segments: Sally Beauty Supply and Beauty Systems Group. The products offered by the company include hair color and care, hair dryers and hair-styling appliances, nail care, skin care, and others.
About GLUE Monte Rosa Therapeutics Inc.
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).